Back to Headlines
Politics
Apr 28, 2026
Analyzed by GPT OSS 120B

Trump Signs Executive Order to Fast‑Track Psychedelic Medicines, Backed by RFK Jr. and Silicon Valley

AI Summary
President Donald Trump signed an executive order on 18 April 2026 to accelerate medical access to psychedelic drugs, a move championed by Robert F. Kennedy Jr. and backed by tech moguls. The policy shift reflects a broader right‑wing embrace of psychedelics as a lucrative mental‑health solution and signals a new era of investment and regulation.

Executive Order Accelerates Psychedelic Access in the White House

The White House announced a new presidential executive order on 18 April 2026 that streamlines federal approval for psychedelic‑based therapies, with a particular focus on ibogaine. The signing ceremony featured Donald Trump, Robert F. Kennedy Jr. and podcaster Joe Rogan, underscoring the political weight behind the initiative.

From Senate Hearings to Presidential Sign‑off: The 60‑Year Turnaround

  • 1966 – Senator Ted Kennedy interrogates Timothy Leary about LSD, labeling it “dangerous”.
  • 2023 – Former Texas Governor Rick Perry publicly supports psychedelic legalization.
  • 2024 – Google co‑founder Sergey Brin invests $15 m in ibogaine research.
  • 2026 – Donald Trump signs the executive order, marking a dramatic policy reversal.

Market Projections: Psychedelic Mushroom Industry Poised for $3.3 bn by 2031

Forbes predicts the global psychedelic‑mushroom market will exceed $3.3 billion by 2031, driven by expanding legal frameworks and rising demand for novel mental‑health treatments. Earlier funding rounds illustrate the capital influx: a 2020 $125 m round backed by Peter Thiel, and a 2024 $15 m injection from Sergey Brin.

Political Realignment: Why the Right Embraces Psychedelic Medicine

Several factors explain the right‑wing pivot:

  • Clinical evidence linking psychedelics to improvements in depression, PTSD and suicidal ideation.
  • Veteran and law‑enforcement advocacy groups lobbying for therapeutic access.
  • Recognition of the lucrative market, attracting Silicon Valley investors and Republican donors.

What Comes Next? Regulation, Investment, and the Future of Mental‑Health Care

Looking ahead, the landscape will be shaped by:

  • Federal regulatory pathways that balance rapid approval with safety oversight.
  • Continued venture‑capital inflows, potentially accelerating drug‑development pipelines.
  • Political dynamics as both Democrats and MAGA Republicans champion psychedelic reform, while traditional conservatives weigh public perception.

The convergence of policy, science, and finance suggests that psychedelics could become a mainstream component of mental‑health treatment within the next decade, but the ultimate trajectory will depend on how quickly regulatory frameworks adapt and who controls the emerging market.